Longboard Pharmaceuticals
Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases. The company leverages over 20 years of GPCR research to develop highly selective small molecule product candidates targeting G protein-coupled receptors (GPCRs). It aims to address significant unmet needs in conditions such as developmental and epileptic encephalopathies, including Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex, and CDKL5 deficiency disorder. Recently acquired by Lundbeck, Longboard continues to advance its pipeline of CNS-targeted therapies.
Industries
Nr. of Employees
small (1-50)
Longboard Pharmaceuticals
4275 Executive Square, Suite 950, La Jolla, CA 92037
Products
LP352 (bexicaserin)
Oral, centrally acting 5-HT2C receptor superagonist candidate developed for the potential treatment of seizures associated with developmental and epileptic encephalopathies; evaluated in Phase 1 and Phase 1b/2a studies with PK/PD and safety assessments.
LP659
Oral, centrally acting sphingosine-1-phosphate (S1P) receptor modulator candidate in IND-enabling development for treatment of neurological diseases associated with neuroinflammation.
LP143
Oral, centrally acting full cannabinoid type 2 (CB2) receptor agonist candidate under preclinical development for potential treatment of CNS diseases associated with neuroinflammation.
LP352 (bexicaserin)
Oral, centrally acting 5-HT2C receptor superagonist candidate developed for the potential treatment of seizures associated with developmental and epileptic encephalopathies; evaluated in Phase 1 and Phase 1b/2a studies with PK/PD and safety assessments.
LP659
Oral, centrally acting sphingosine-1-phosphate (S1P) receptor modulator candidate in IND-enabling development for treatment of neurological diseases associated with neuroinflammation.
LP143
Oral, centrally acting full cannabinoid type 2 (CB2) receptor agonist candidate under preclinical development for potential treatment of CNS diseases associated with neuroinflammation.
Services
Sponsorship and operational execution of Phase 1 through Phase 1b/2a studies in healthy volunteers and patients for CNS small molecules.
Preclinical efficacy testing in seizure models and conduct of studies required to support regulatory IND submissions.
Sponsorship and operational execution of Phase 1 through Phase 1b/2a studies in healthy volunteers and patients for CNS small molecules.
Preclinical efficacy testing in seizure models and conduct of studies required to support regulatory IND submissions.
Expertise Areas
- Clinical trial management for CNS therapeutics
- GPCR-focused small molecule drug discovery
- Translational pharmacology and biomarker development
- Preclinical seizure model evaluation
Key Technologies
- GPCR-targeted small molecule chemistry
- Plasma and CSF pharmacokinetic assays
- Pharmacodynamic biomarkers (prolactin) and QEEG
- Zebrafish and preclinical seizure models
News & Updates
On December 2, 2024, Lundbeck announced the successful acquisition of Longboard Pharmaceuticals, making it a wholly owned subsidiary.
Presentation of Phase 1 data for LP352 in healthy volunteers, highlighting safety, tolerability, pharmacokinetics, and receptor engagement.
On December 2, 2024, Lundbeck announced the successful acquisition of Longboard Pharmaceuticals, making it a wholly owned subsidiary.
Presentation of Phase 1 data for LP352 in healthy volunteers, highlighting safety, tolerability, pharmacokinetics, and receptor engagement.